Carlo Manno

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6147710/publications.pdf

Version: 2024-02-01

471509 677142 23 1,628 17 22 citations h-index g-index papers 25 25 25 1917 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrology Dialysis Transplantation, 2009, 24, 3694-3701.	0.7	256
2	Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney International, 2004, 66, 1570-1577.	5.2	243
3	Multicenter Study on Hepatitis C Virus–Related Cryoglobulinemic Glomerulonephritis. American Journal of Kidney Diseases, 2007, 49, 69-82.	1.9	193
4	Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology, 1997, 25, 1237-1244.	7.3	155
5	A Novel Simpler Histological Classification for Renal Survival in IgA Nephropathy: A Retrospective Study. American Journal of Kidney Diseases, 2007, 49, 763-775.	1.9	153
6	Desmopressin Acetate in Percutaneous Ultrasound-Guided Kidney Biopsy: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2011, 57, 850-855.	1.9	93
7	Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 392-401.	1.9	85
8	Increased Risk of End-Stage Renal Disease in Familial IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2002, 13, 453-460.	6.1	71
9	An "evidence-based―survey of therapeutic options for IgA nephropathy: assessment and criticism. American Journal of Kidney Diseases, 2003, 41, 1129-1139.	1.9	70
10	Beta-Glucans Supplementation Associates with Reduction in P-Cresyl Sulfate Levels and Improved Endothelial Vascular Reactivity in Healthy Individuals. PLoS ONE, 2017, 12, e0169635.	2.5	54
11	Para- and perirenal ultrasonographic fat thickness is associated with 24-hours mean diastolic blood pressure levels in overweight and obese subjects. BMC Cardiovascular Disorders, 2015, 15, 108.	1.7	52
12	Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy. Kidney International, 2021, 99, 1179-1188.	5.2	47
13	Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. Clinical and Experimental Medicine, 2019, 19, 1-21.	3.6	39
14	Relationship of para- and perirenal fat and epicardial fat with metabolic parameters in overweight and obese subjects. Eating and Weight Disorders, 2019, 24, 67-72.	2.5	28
15	Alport syndrome and leiomyomatosis: the first deletion extending beyond COL4A6 intron 2. Pediatric Nephrology, 2011, 26, 717-724.	1.7	27
16	Treatment with rituximab in idiopathic membranous nephropathy. CKJ: Clinical Kidney Journal, 2016, 9, 788-793.	2.9	22
17	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome). European Respiratory Journal, 2021, 57, 2004158.	6.7	19
18	Treatment of glomerulonephritides associated with hepatitis C virus infection. Nephrology Dialysis Transplantation, 2000, 15, 34-38.	0.7	9

#	Article	IF	CITATIONS
19	Randomized clinical study to evaluate the effect of personalized therapy on patients with immunoglobulin A nephropathy. CKJ: Clinical Kidney Journal, 2022, 15, 895-902.	2.9	6
20	Conversion from Epoetin and Darbepoetin to C.E.R.A. in Non-Dialysis CKD Patients: A Multicenter Italian Prospective Study in Nephrology Practice. Blood Purification, 2013, 36, 69-77.	1.8	4
21	Therapeutic aspects of IgA nephropathy: an overview. Nephrology, 2002, 7, S156.	1.6	1
22	MO260PERFORMANCE ANALYSIS OF AN ARTIFICIAL NEURAL NETWORK TOOL TO PREDICT ESKD IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN). Nephrology Dialysis Transplantation, 2021, 36, .	0.7	1
23	Therapeutic aspects of IgA nephropathy: an overview. Nephrology, 2002, 7, S156-S163.	1.6	0